Aquinox sinks on Phase II COPD data

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) plummeted $4.42 (67%) to $2.13 on Thursday after AQX-1125 failed in the Phase II FLAGSHIP trial to treat chronic obstructive pulmonary disease in patients with a history of frequent exacerbations. Patients receiving AQX-1125 showed no difference in COPD symptoms as measured by the patient-reported EXACT tool, the study's primary endpoint, vs. placebo.

Aquinox said it will continue to develop AQX-1125 in bladder pain syndrome/interstitial cystitis (BPS/IC). The company said last month that the SH2-containing inositol 5'-phosphatase (SHIP) agonist showed signs of efficacy but did not significantly reduce pain compared to placebo (p=0.061) in the Phase II LEADERSHIP trial to treat BPS/IC. ...